Menu
Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.
RemoteCare Tissue Processing

RemoteCare 24 hour Remote Monitoring of your Lab Equipment

Leica Biosystems Receives US Patent for RTF Extreme Speed Scanning Technology

VISTA, CA – January 7th, 2019 – Leica Biosystems, the global leader in pathology workflow solutions announced today that the US Patent Office has granted it a patent for RTF, its breakthrough “Real-Time Focusing” technology (US patent 9,841,590). This will enable high volume, extremely fast line scanning of anatomic pathology slides.

“RTF technology dramatically improves slides scanning speed while delivering excellent optical focus. Extremely short scan times can now be achieved at 40x magnification,” said Jerome Clavel, General Manager of Leica Biosystems Pathology Imaging. “We have been working internally with RTF technology for quite some time. We will be integrating and commercializing RTF into our next-generation digital pathology platform shortly.”

Leica Biosystems has been testing RTF with UCLA (University of California, Los Angeles), and other leading institutions worldwide to fine-tune its application in a high-volume laboratory setting.

“We are excited about the potential of RTF to significantly scale up digital pathology operations by moving high volume and high throughput scanning into the histology lab,” said Dr. W. Dean Wallace, Professor, Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA. “By implementing RTF technology into our workflow, we will soon be able to take the next crucial step in the development of digital pathology.”

Leica Biosystems has a large global R&D footprint with 12 development centers. Its dedicated teams of engineers develop innovative technologies with the goal of enabling pathologists to efficiently make highly confident same-day diagnoses. Aperio Technologies, now part of Leica Biosystems, introduced high-speed line scanning into Digital Pathology years ago, and holds a comprehensive patent portfolio for this technology in key geographies.

The statements in this press release are forward looking and any references to projected timelines, anticipated functionality or potential claims are only speculative at this state.

Aperio digital pathology products using RTF have not been cleared for clinical diagnostic use in the U.S.A.

About Leica Biosystems

Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is headquartered in Germany and operates in over 100 countries.

Multiplex fluorescence immunohistochemistry using the Ultivue InSituPlex platform on the Leica Biosystems BOND RX

Register Now for On Demand

Abstract:

Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the analysis of target protein expression in subsets of specific cells within the context of histopathological features of disease. However, the multiplexing capabilities of fluorescence IHC, using standard histology equipment, are subject to several technical challenges. This webinar will provide insight and examples of how the Ultivue InSituplex platform may be used to address several of the current challenges associated with multiplex fluorescence immunohistochemistry. It will focus on initial user experiences using the InSituPlex platform using automated IHC on the Leica Biosystems BOND RX and automated imaging with the Leica Biosystems Aperio Versa.

Learning Objectives:

  • Understanding technical challenges associated with tyramide-based multiplex fluorescence IHC.
  • What tools are available today for mulitplex?

 

Speakers:


Traci DeGeer

Global Product and Innovation Manager-BOND RX Leica Biosystems

 


Alexander Klimowicz

Principal Scientist, Boehringer Ingelheim Pharmaceuticals

 

 

Non-small lung cancer, stained with PD-L1 BOND Ready-to-Use Primary Antibody (73-10), PA0832

A new PD-L1 BOND-Ready-to-Use antibody, providing you with the freedom and flexibility to develop the tests you need

NEWCASTLE, ENGLAND, UK NOVEMBER 2018 – Leica Biosystems, a leading provider of pathology products and solutions, globally launched a new PD-L1 antibody for use on their fully automated BOND IHC and ISH staining platform.

The new PD-L1 (programmed death - ligand 1) antibody uses the MKP1A07310 (clone 73-10) expressed by UK - based Abcam on behalf of Merck KGaA, Darmstadt, Germany, which owns all IP rights to this antibody. It joins the recently released ALK (anaplastic lymphoma kinase) antibody as the latest addition to Novocastra’s growing lung menu of primary antibodies.

Leica Biosystems’ Newcastle, UK team have deep knowledge and expertise in end-to-end antibody development and manufacturing, and have optimized these two clones into a ready-to-use format for use on the BOND IHC and ISH staining platform. This allows labs to perform ALK and PD-L1 testing on the BOND system with rapid turnaround times, reliable staining and walk-away convenience.

“Cancer remains a leading cause of death and a devastating diagnosis for patients,” said Colin White, PhD, global vice president of Advanced Staining at Leica Biosystems. “The PD-L1 and ALK ready-to-use antibodies are tools that can provide valuable supporting diagnostic information to the pathologist, with all the efficiency benefits of the BOND system.”

John Baker, senior vice president of portfolio and business development at Abcam, added: “Our antibody scientists have extensive experience developing the high-quality antibodies to critical biomarkers such as PD-L1 required for use in diagnostic platforms, where using the right antibody is crucial to patient health outcomes. Working closely with colleagues at Leica, we succeeded in integrating this antibody into their BOND diagnostic platform to enable accurate analysis of PD-L1 in formalin fixed, paraffin embedded tissue.”

About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.

About Abcam
Abcam is an innovator in reagents and tools. Its purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the company offers highly validated biological binders and assays to address important targets in critical biological pathways. Abcam’s 11 locations are in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, U.K., the company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

 

Unlocking the complexities of cancer biology with BOND RX and Ultivue.

Melbourne, Australia and Cambridge, Massachusetts – September 14, 2018 | Leica Biosystems and Ultivue begin Co-Marketing of UltiMapper Assay on the BOND RX enabling single-step automated multiplexing in under 6 hours.

Building on its legacy of partnering with emerging technology leaders, Leica Biosystems have partnered with Ultivue and announced the co-marketing of Ultivue’s UltiMapper assays with Leica Biosystems’ BOND RX research staining platform1 enabling rapid automated multiplex biomarker detection.

The Ultivue UltiMapper single step multiplexing assay is pre-optimized for the BOND RX enabling a fully automated plug-and-play solution resulting in the creation of 30, five color, high performance immunohistochemistry multiplexing slides in under 6 hours while preserving tissue morphology and integrity. Ultivue’s unique DNA barcode attached to each antibody allows all antibodies to be stained in a single step, taking the typical multi-day manual multiplex test and transforming it into a process that can fit into a standard workday. UltiMapper and BOND RX perfectly complement one another, freeing up researchers’ time from perfecting difficult manual techniques, allowing them to focus on analyzing the results.

Leica Biosystems offers researchers the opportunity of a complete end-to-end workflow solution. Automated staining of the UltiMapper assay on the BOND RX and slide scanning and quantification using the Aperio VERSA fluorescence tissue scanner and Aperio Cellular IF Algorithm2 brings new technologies to more researchers.

“With tissue sample sizes decreasing, and scientific advancements expanding the number of actionable biomarkers, multiplexing is an increasingly common technique used by researchers to explore complex biology” said Colin White PhD, Global Vice President of Advanced Staining at Leica Biosystems. “We are very pleased to be able to offer investigators an automated version of Ultivue’s UltiMapper multiplexing technology on the BOND RX thereby supporting research excellence through workflow efficiency and stain consistency”.

“We are delighted to partner with Leica Biosystems to bring to the Research market, a complete automated solution to realize the full potential of tissue-based, multiplexed marker studies at high throughput,” said Philippe Mourere, Senior Vice President of Commercial Operations at Ultivue. “Through our growing immuno-oncology portfolio of kits and assays, translational and clinical researchers have immediate access to unbiased biology with the ability to co-localize markers on single cells, and to functionally characterize cellular interactions within the tumor microenvironment. Looking ahead, we are expanding our level of multiplexing and widening our content offering to adjacent research areas.”

1. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES
2. Other whole slide imaging and analysis options are available

About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. The company is headquartered in Germany and operates in over 100 countries with manufacturing facilities in 9 countries. Visit LeicaBiosystems.com for more information.

About Ultivue
Multiplexed biomarker assays in tissue for personalized medicine research and clinical pathology.
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and clinical use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine tools. Ultivue is expanding its UltiMapper assay product portfolio and menu of contract research services to provide a comprehensive set of personalized medicine solutions for oncology and other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit Ultivue.com

Partnership of Leeds Teaching Hospitals NHS Trust with Leica Biosystems Achieves Major Milestone for Cancer Diagnostics

Collaboration to enable large-scale transition from glass slides to digital images for pathology diagnoses across all subspecialties

VISTA, Calif.—Oct. 11, 2018— Leica Biosystems the cancer diagnostics leader achieved a major digital pathology milestone in its multiyear collaboration with Leeds Teaching Hospitals NHS Trust in the UK. In alignment with the company’s VISION24 initiative, this heralds a revolution in the way that cancer and other diseases can be diagnosed.

Pairing technology, systems and support from Leica Biosystems with medical and scientific expertise from Leeds, the collaboration has resulted in 100 percent digital conversion of the hospital’s glass slides workflow. Looking ahead, it promises to enable a large-scale transition from glass slides to digital images for clinical diagnoses across all subspecialties.

“This positions Leeds as a leader in digital pathology for clinical use,” said Darren Treanor, consultant pathologist and lead for the Digital Pathology Project at Leeds Teaching Hospitals NHS Trust. “In partnership with Leica Biosystems, we have created a template and supporting information for other major medical centers around the world to consider as they make the journey to the digital future of cancer diagnostics.” Leeds is now scanning its glass slides ramping up to approximately 1,000 per day. Digital slides have the advantage of enabling high resolution enlarged views. They also allow secure sharing with other clinicians even in remote locations for additional consultation.

The ultimate goal of this collaboration is greater lab efficiency and diagnostic confidence in less time for patients. The specific actions taken at Leeds include:

  1. 100% digitization of the slides workflow of the Leeds histopathology lab.
  2. Comprehensive and practical validation process to promote pathologists’ acceptance of digital pathology
  3. Knowledge-sharing through digital pathology workshops attended by more than 55 institutions over the last 18 months and multiple industry publications.
  4. Publishing the "The Leeds Guide to Digital Pathology", a comprehensive overview which outlines the benefits of transitioning to digital pathology:

    • Improvements in Patient Safety
    • Advances in Workflow
    • Positive Impact on Laboratory Staff
    • Higher Service Quality

These objectives align with Leica Biosystems’ VISION24 initiative.

“VISION24 reflects Leica Biosystems’ focus on innovation—a future in which clinicians from various specialties work seamlessly together to provide patients with a highly accurate diagnosis, consistently and efficiently, within 24 hours of biopsy,” explained Melissa Aquino, President of Leica Biosystems. “As experts in the workflow from biopsy to diagnosis, we continually innovate to provide the tools and technology, the systems and processes, that will deliver pathology’s great promise to transform cancer diagnostics for the benefit of patients.”

The clinical use claims described in the information provided have not been cleared or approved by the U.S. Food and Drug Administration, nor are the products available in the United States.

About Leica Biosystems
Leica Biosystems is a global leader in cancer diagnostics with the most comprehensive portfolio from biopsy to diagnosis. We are committed to delivering Accuracy, Quality and Workflow Efficiencies to help advance diagnostic confidence.

About Leeds NHS Trust
Leeds Teaching Hospitals NHS Trust is one of the largest teaching hospitals in Europe, a regional and national center for specialist treatment, a world-renowned biomedical research facility and a leading clinical trials research unit. This means we have access to some of the U.K.’s leading clinical expertise and the most advanced medical technology in the world. With a £1 billion budget, we provide local and specialist services for our immediate population of 770,000 and regional specialist care for up to 5.4 million people. We have one of the largest single hospital pathology departments in the country.

For Breast Biopsies, MammoPort Standardizes Tissue Transfer from Radiology to Pathology to Ensure Quality and Reduce Errors

New from Leica Biosystems, first integrated specimen containment and transport system promises to enhance efficiency and diagnostic confidence.

RICHMOND, Ill.— October 2, 2018 — Leica Biosystems, the leader in cancer diagnostics from biopsy to diagnosis, today announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system for breast tissue biopsies, which average 1.6 million a year in the United States alone.

“Mammoport is the only tissue containment system which unites Pathology and Radiology colleagues in their common desire for maintaining tissue integrity throughout the entire radiological tissue acquisition to the pathologic diagnostic process,” says Dr. Darius R. Gilvydis, MD, an internationally renowned Breast Imaging Specialist.

Integrated Solution for Safety and Efficiency. With medical errors representing a leading cause of death, experts recommend developing consensus protocols that streamline the delivery of medicine and reduce variability to improve quality and lower costs in health care. By integrating MammoPort with Mammotome revolve breast biopsy device, for the first time the tissue containment and transport system is standardized, minimizing the potential for error and tissue damage.

“By standardizing the process of transferring breast biopsy tissue from the radiology suite to the pathology lab, MammoPort maintains the quality of core specimens,” said Peter Reimer, Vice President of Core Histology at Leica Biosystems. “This integrated containment and transport system—the first of its kind—sets a new standard of quality for transferring tissue to ensure an efficient and confident diagnosis by the pathologist.”

Eliminate Manual Handling of Tissue. Current breast biopsy methods require over 300 different processing steps and 14 interdepartmental handoffs, resulting in an increased chance for tissue damage, according to Heather Renko-Breed, Global Product Manager at Leica Biosystems. MammoPort eliminates the need for manual tissue handling by radiology technologists, protecting the quality of the biopsied tissue and enhancing ease-of-use.

“Mammoport is the first system to completely eliminate unnecessary tissue manipulation and calcification separation, therefore maintaining critically important tissue orientation, size, and integrity,” indicates Dr. Gilvydis. “This is performed without crush damage to the tissue from tweezers as with other systems. This maintenance of tissue integrity allows improved diagnostic accuracy, which can lead to improved patient treatment and outcomes.”

The Mammotome revolve breast biopsy device automatically places the tissue into the tissue trays. The radiology technologist then inserts the tray with the samples into the Mammoport container, and it is transported to the radiograph. Once the calcifications are confirmed, the radiology technologist marks the container with the breast cores of interest, placing it into formalin for seamless transport to the Pathology lab for grossing and processing.

Improved Calcification Separation. MammoPort eliminates the need to manually separate tissue with calcifications from non-calcifications, helping prevent potential medical errors. The specimens remain individually contained to maintain the orientation and location of the calcifications, and the marked container helps to ensure the proper patient information and critical specimen identification of calcifications remain intact throughout the process.

“The hard work of detecting the breast abnormality, acquiring the tissue during the biopsy process, can all be undone by manual crush manipulation during the separation of tissue and calcifications,” says Dr. Gilvydis. “Mammoport eliminates this pitfall and helps bridge tissue integrity throughout the acquisition and diagnostic process from Radiology to Pathology.”

MammoPort is a trademark of Leica Biosystems, Richmond, Inc. in the USA and optionally in other countries. For more information, visit https://www.leicabiosystems.com/histology-consumables/archiving-transport-storage/specimen-transport-storage/products/mammoport/.

About Leica Biosystems

Leica Biosystems is a global leader in cancer diagnostics with the most comprehensive portfolio from biopsy to diagnosis. We are committed to delivering Accuracy, Quality and Workflow Efficiencies to help advance diagnostic confidence.

Visit LeicaBiosystems.com for more information.

The HistoCore SPECTRAWorkstation is the firstand only workstationwith dual glass coversliplines, enabling the highestthroughput of up to 570dried slides per hour, tomeet the most demandingturnaround times.

For High-Volume Pathology Labs, HistoCore SPECTRA Workstation Delivers Immediately Dry Slides atFaster TurnaroundTimes

Integrating revolutionary technology from Leica Biosystems offers exceptionally high throughput and consistent staining quality to enhance efficiency and diagnostic confidence.

NUSSLOCH, GERMANY, 10 SEPTEMBER, 2018. Leica Biosystems, the cancer diagnostics company, today announced the global launch of the HistoCore SPECTRA Workstation, which integrates the HistoCore SPECTRA ST stainer with the new HistoCore SPECTRA CV coverslipper, for an all-in-one platform that enhances efficiency and diagnostic confidence for large-volume pathology labs by delivering exceptionally high throughput and consistentstaining quality.

“For consistency, efficiency and quality, we turned to the HistoCoreSpectra Workstation,” said Christopher Hospidales, Manager, Anatomic Pathology, Wisconsin Diagnostic Laboratories. “The HistoCore SPECTRA Workstation helps us to consistently provide the highest quality slides to our pathologist. It is important to know the staining quality of the first slide will be the very same on the 1600th slide. It provides a level of confidence that we did not fully experience before.”

The HistoCore SPECTRA workstation is the first and only workstation with dual-glass coverslip lines, enabling the highest throughput of up to 570 dried slides per hour. The integrated coverslipper oven delivers unmatched glass-slide drying times of just 5-minutes providing immediately dry slides to pathologists for quicker diagnosis.

Lab managers appreciate the flexibility to run multiple protocols in parallel by processing H&E and special stains simultaneously, increasing efficiency by 20 percent compared to other platforms. RFID tracking of consumables further supports easy-to-manage staining.

“The next-generation HistoCore SPECTRA workstation is an innovative solution that standardizes several steps in the staining and coverslipping process for faster turnaround times and produces high-quality slides required by the pathologist,” said Peter Reimer, PhD, Vice President Core Histology, Leica Biosystems. “This integrated system features unique coverslipper technology that streamlines the histology process, supporting pathology labs that are challenged to meet the demands of increased workloads.”

Several advanced features reduce hands-on time for Histotechs, helping prevent errors. RFID technology facilitatescoverslipperautostart and displays the number of slides left to coverslip until exhaustion; the reagent management system’s proprietary fill-level scan system ensures stain reproducibility; and the unique color-coded rack application starts individual protocols automatically when racks are inserted. Additionally, the coverslipper’s unique broken-glass detector sensor removes and transfers broken coverslips for improved safety.

“With these ground-breaking advances, the HistoCore SPECTRA Workstation promises to enhance the quality, the safety and the speed at which labs deliver diagnosable glass-coverslipped slides in today’s demanding environment,” said Reimer.

About Leica Biosystems Leica Biosystems is a global leader in cancer diagnostics with the most comprehensive portfolio from biopsy to diagnosis. We are committed to delivering Accuracy, Quality and Workflow Efficiencies to help advance diagnostic confidence.

Visit LeicaBiosystems.com for more information.

LEICA BIOSYSTEMS APERIO LV1 IVD APPROVED FOR REMOTE FROZEN SECTION AND TELEPATHOLOGY*

VISTA, CA – July 31st, 2018 – Leica Biosystems, the global leader in pathology workflow solutions, announced today that its live view telepathology system, the Aperio LV1 IVD, can now be used for on-screen diagnosis in Europe**, Canada, Australia and New Zealand.

This compact Digital Pathology system, with a capacity of 4 slides, navigates like a conventional microscope, but with a host of digital benefits. Live View with robotic controls enables real-time telepathology with remote access to slides in less than 15 seconds. It can also function as a low volume, whole-slide scanner, and its small footprint fits easily into limited laboratory space.

With In Vitro Diagnostic CE Mark, as well as Therapeutics Goods Administration (TGA) and Health Canada registrations, customers in Europe, Australia, New Zealand, and Canada can now use the Aperio LV1 IVD for diagnostic reads of frozen sections and regular FFPE histology slides.

“These registrations allow our customers to use the Aperio LV1 IVD for clinical diagnosis as part of their daily anatomic and surgical pathology workflows,” said Jerome Clavel, General Manager of Leica Biosystems Pathology Imaging business. “Real-time digital access to slides is critical for pathologists to provide remote frozen section consultations and slide reads from their office, or any other location.”

The clinical use claims described in the information provided have not been cleared or approved by the U.S. FDA nor are the products available in the United States.

About Leica Biosystems:
Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

 

* Requires at least a 50 megabit per second (Mbps) internet connection using Team Viewer software (v10) and Aperio LV1 IVD console software (v4.0) with one slide loaded in the slide tray. 15 second time starts once the Team Viewer “Log On” is selected.

**Aperio LV1 IVD is now available in certain European countries only. Contact your Leica Biosystems representative for more information.

INSPIRING INNOVATION, LEICA BIOSYSTEMS INTRODUCES THE NEXT-GEN BOND RX IHC, ISH AND EMERGING TESTS STAINER

Melbourne, Australia – June 18, 2018 - Simplify your research in cancer biology and discover new approaches to diagnosis with the new BOND RX next generation research stainer by Leica Biosystems.

The BOND RX system provides researchers with the ability to design their ideal protocol. With customization options across all protocol editing segments, the BOND RX enables greater flexibility when optimizing conditions for a variety of test types including IF, ISH, FISH, TUNEL, TSA, CTC, Multiplexing and other emerging tests.

Geared toward expanding the user’s freedom to discover, the latest advances to the BOND RX include enhancements to improve the overall user experience. Coupled with an expansion to the system’s customization capabilities, researcher’s now have more options to explore their ideas.

Primary Features of the new BOND RX include:

  • Protocol Customization Advancements

    • Customize your dewax options. Add or subtract as many dewax steps as needed.
    • Choose from six unique probe application and removal protocols. Select the protocol
    • that best suits your probe.
    • Select your dispense type with a choice of 3 different reagent flow options.

  • Reagent Visual Management Lighting System

    • Reagents are illuminated and provide clear visual alerts to users at a glance.

  • New software version 6.0

    • New highly visual user interface with easy to identify iconography.

“With science advancing at such a rapid rate, it is an exciting time to be supporting researchers as they seek to unlock the complexity of cancer biology and develop new approaches to diagnosis” said Colin White, PhD Global Vice President – Advanced Staining at Leica Biosystems. “The release of the next generation of BOND RX is an important milestone in providing our customers with broader experimental flexibility and improved usability”.

Leica Biosystems has an open system across the workflow and an optimized product portfolio that offers you the reproducibility and flexibility you need to uncover critical details. Spend less time on manual tasks and more time innovating to find answers – helping you obtain the data needed to secure funding for that next breakthrough discovery. The new BOND RX automated researcher stainer, featuring enhanced usability and increased protocol editing flexibility is available in USA.

About Leica Biosystems

Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Rotary Microtome Solutions Provide Pathology Labs High Quality Sectioning and Enhanced User Safety

Nussloch, Germany,30 May2018. Leica Biosystems announcesthe addition of a new family of Rotary Microtomes to its full line of histology equipment and consumables. The line-up includes the HistoCore BIOCUT, HistoCore MULTICUT and HistoCoreAUTOCUT clinical microtomes. Each instrument provides high quality sections and ease of use, while delivering enhanced safety for the user.

“We are very excited to introduce the next generation of clinical microtomes based on our 145 years of experience in microtomy," stated Peter Reimer, Vice President Core Histology, Leica Biosystems. “Through listening to our customers, we have developed a family of microtomes that will help provide consistent quality and enhanced efficiency, while maintaining a safe and healthy workplace for the user,” said Reimer.

Head of Laboratory, Mengia Berthold and Deputy Head of Laboratory, Karin Portmann, Pathology Laenggasse stated, “After using the HistoCore MULTICUT and AUTOCUT, we noticed the stability of the instruments and high quality sectioning. The new coarse feed wheels allows us to trim our blocks faster, and the antistatic waste tray makes cleaning quick and easy. Our lab techs immediately noticed the new product design and the larger surface top for storing tools and consumables.”

The HistoCore Rotary Microtomes deliver improved comfort through ergonomic positioning and adapting the coarse feed wheel to the user’s preference, helping reduce fatigue while trimming. In addition, the unique force balance system reduces the risk of injury froman unbalanced object head.

For increased flexibility, users can produce high quality paraffin sections for H&E, IHC and molecular techniques. Additionally, a 2-in-1 blade holder providesthe flexibility to use both high and low profile blades.

An optional antistatic waste tray increases efficiency by shortening cleaning time from minutes to seconds and reduces contamination to the user/environment by effectively collecting and containing waste. Also, a specimen cooling option allows for the block temperature to stay colder longer using the electrically cooled RM CoolClamp for standard cassettes.

The HistoCoreRotary Microtomes offer rapid specimen exchange withfast homing and programmable memo position (MULTICUT and AUTOCUT) and an electronic brake for safe blade and specimen handling (AUTOCUT).

About Leica Biosystems

Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.